Myriad Genetics reported an 11% year-over-year increase in both fourth-quarter and full-year revenue, achieving $197 million and $753 million, respectively. The company delivered GAAP EPS of $(0.36) and adjusted EPS of $0.04 for the quarter. Looking ahead, Myriad is raising its 2024 revenue guidance to $820 - $840 million and introducing adjusted EPS guidance of $0.00 - $0.05.
Full-year testing volume grew 35% year-over-year, or 18% ex-SneakPeek® volume.
Fourth quarter GAAP operating expenses and adjusted operating expenses each decreased by 6% year-over-year.
Fourth quarter adjusted cash flow from operations increased by $10 million year-over-year to $14 million.
Myriad Genetics acquired select assets from Intermountain Precision Genomics in February 2024.
Myriad Genetics raised its full-year 2024 revenue guidance to $820 - $840 million, reflecting annual growth of 9% - 11%. Adjusted EPS is projected to be between $0.00 and $0.05. Q1 2024 revenue is expected to grow at a mid-to-high single-digit percentage rate year-over-year, with acceleration throughout the year.
Analyze how earnings announcements historically affect stock price performance